BLOG
Notice of Proposed Rule by DEA Regarding CSOS
Notice of Proposed Rule by DEA Regarding CSOS | by: Deneen Fumich, RPh | Article Posted: March 1, 2023 | On February 2, 2023, the Federal Register included the notice of proposed rulemaking by the DEA for the purpose to amend the regulations to conform to the...
Recent Articles
Licensing Issues Causes Public Skirmish with State Boards for Drug Companies
The patchwork that is state licensure is a constant challenge for all companies in the pharmaceutical supply chain – from international drug manufacturers to independent distributors. Companies not in compliance are at significant risk of being caught by state agencies and facing significant fines, having disciplinary action follow them for years, and, in one example, being forced to close their business. Most important to remember is that non-compliance typically sets off a chain reaction.
DSCSA to Cause Future State Regulation Changes
DSCSA to Cause Future State Regulation Changes State regulation of the pharmaceutical supply chain is a patchwork of different definitions,...
Morphine Equivalency for Suspicious Order Monitoring
Morphine Equivalency for Suspicious Order Monitoring Background In July 2016, at the height of the opioid epidemic, the West Virginia Attorney...
Minnesota Board of Pharmacy Fee is a Barrier to Entry
The 2,200% increase for Minnesota fees has created an unprecedented barrier to entry for small wholesalers and start-up manufacturers. Of our clients, 25% have decided to forego licensure in the state– typically smaller wholesalers and virtual manufacturers who have not yet started a business within the state.
PBMs Turn Up the Pressure on Diabetic Test Strip Reimbursements
Two separate PBMs recently issued audits to an independent pharmacy because it was determined that the pharmacy was sourcing diverted test strips from an NABP DDA (fka VAWD®) Accredited facility.
Optum Rx & NABP DDA Lawsuit Update
Optum Rx’s requirement for their network pharmacies to only purchase prescription drug and diabetic testing supplies from Accredited wholesalers has caused significant disruption and controversy since its implementation in August 2016. The requirement spurred two separate lawsuits. The second, which continues in full force, has a recent amended complaint – and Pharma Solutions has unique insight into the lawsuit’s developments.
